Lexaria Bioscience Corp.
corporate_fare Company Profile
Lexaria Bioscience Corp. (NASDAQ:LEXX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for LEXX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-17, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for LEXX spans 8-K, 10-Q, 424B3.
Recent high-impact activity:
- Lexaria Secures $7.9M, Extends Cash Runway Through 2027
- Lexaria Raises $5.9M via Warrant Inducement, Adds 907,938 New Warrants
- Lexaria Banks AUD$3.7M (USD$2.6M) Australian R&D Tax Credit
- Lexaria Regains Nasdaq Compliance, Delisting Hearing Cancelled
- Lexaria Inks GLP-1 Deal With PegBio, Stock Jumps 29%
Financial Snapshot
Short Interest & Short Volume
5.40 days to coverFINRA reported short interest of 217,377 shares in LEXX as of the October 30, 2026 settlement, a 15.0% decrease from the prior period — about 5.4 days to cover at its recent average daily volume. On November 20, 2026, 28.5% of LEXX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for LEXX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-09.
Warrant Inducement Raises $5.9M · New Warrants Add Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →